Viking Therapeutics is expected to report a consensus EPS loss of $1.21 on zero revenue for the second quarter of 2026, with its current price of $33.80 trading significantly below the average analyst target of $93.60.
Investors are primarily focused on the clinical progress of VK2735, specifically the upcoming readout of maintenance dosing data and updates on the dual GLP-1/GIP obesity pipeline.
Management recently achieved full enrollment for the subcutaneous Phase 3 VANQUISH trials and plans to initiate a pivotal oral study in late 2026. While R&D expenses have surged to roughly $150 million, Wall Street maintains a bullish outlook on the company's competitive position against market leaders Eli Lilly and Novo Nordisk.